Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain

The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes

Revvity establishes In Vivo Imaging Center of Excellence in North Carolina

Facility designed to advance the next generation of imaging systems

India preparing to become hub for medical technology: Pharmaceuticals Secretary

Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth

Bayer presents Phase III VICTOR clinical trial data of vericiguat at ESC Congress 2025

The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged

Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity

Replicate will receive research funding and could potentially receive up to approximately US$550 million

FDA approves Teva Pharmaceuticals' first GLP-1 obesity drug

Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market

Lilly's oral GLP-1 orforglipron succeeds in Phase 3 trial

Triggering global regulatory submissions this year for the treatment of obesity

Sai Life Sciences completes Phase II of production block 11 at Bidar

With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL

Zydus Therapeutics reports positive phase-3 results in rare liver disease

Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients

AbbVie to acquire Gilgamesh Pharmaceuticals’ bretisilocin for $1.2 billion